Literature DB >> 17540164

Stopping ras in its tracks.

Channing J Der1, Terry Van Dyke.   

Abstract

Ras interacts with many downstream effectors that regulate complex cytoplasmic signaling networks. In this issue, Gupta et al. (2007) use mouse models of Ras-mediated tumorigenesis to show that the interaction of Ras with a single isoform of phosphatidylinositol 3-kinase (PI3K), called p110alpha (PIK3CA), is critical for tumor formation. This result will stimulate re-evaluation of pharmacological approaches to target Ras for cancer treatment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17540164     DOI: 10.1016/j.cell.2007.05.031

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  6 in total

1.  Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers.

Authors:  Hiromichi Ebi; Ryan B Corcoran; Anurag Singh; Zhao Chen; Youngchul Song; Eugene Lifshits; David P Ryan; Jeffrey A Meyerhardt; Cyril Benes; Jeffrey Settleman; Kwok-Kin Wong; Lewis C Cantley; Jeffrey A Engelman
Journal:  J Clin Invest       Date:  2011-10-10       Impact factor: 14.808

2.  Membrane Recruitment as a Cancer Mechanism: A Case Study of Akt PH Domain.

Authors:  Joseph J Falke
Journal:  Cellscience       Date:  2007

3.  Pancreatic cancer and precursor pancreatic intraepithelial neoplasia lesions are devoid of primary cilia.

Authors:  E Scott Seeley; Catherine Carrière; Tobias Goetze; Daniel S Longnecker; Murray Korc
Journal:  Cancer Res       Date:  2009-01-15       Impact factor: 12.701

4.  Galectin-3 mediates cross-talk between K-Ras and Let-7c tumor suppressor microRNA.

Authors:  Ran Levy; Anat Biran; Francoise Poirier; Avraham Raz; Yoel Kloog
Journal:  PLoS One       Date:  2011-11-15       Impact factor: 3.240

5.  Ras inhibition boosts galectin-7 at the expense of galectin-1 to sensitize cells to apoptosis.

Authors:  Batya Barkan; Adrienne D Cox; Yoel Kloog
Journal:  Oncotarget       Date:  2013-02

6.  Circulating tumor cells as a biomarker of response to treatment in patient-derived xenograft mouse models of pancreatic adenocarcinoma.

Authors:  Robert J Torphy; Christopher J Tignanelli; Joyce W Kamande; Richard A Moffitt; Silvia G Herrera Loeza; Steven A Soper; Jen Jen Yeh
Journal:  PLoS One       Date:  2014-02-19       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.